LPCN

Insider Trades

Name	Value	Action	Price	Current Price
Higuchi John W.Director $81k40k shares BuyApr 7, 2026 $2.03 --
Higuchi John W.Director $252k123k shares BuyApr 6, 2026 $2.05 --
Patel Mahesh V.Director, Officer: Chief Executive Officer $51k25k shares BuyApr 6, 2026 $2.03 --
Patel Mahesh V.Director, Officer: Chief Executive Officer $51k25k shares BuyApr 2, 2026 $2.02 --

News

prnewswire.comLipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154prnewswire.comJun 4

prnewswire.comLipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meetingprnewswire.comMay 19

globenewswire.comAnaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officerglobenewswire.comMay 19

prnewswire.comLipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcaseprnewswire.comMay 18

zacks.comLipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimateszacks.comMay 7

Trade LPCN

About Lipocine Inc.

Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.

CEO: Mahesh V. Patel
IPO Date: Oct 22, 2013

Market Data

Open: $2.35
High: $2.50
Low: $2.29
Volume: 120.2K
Avg Volume: 402.5K
52W High: $12.37
52W Low: $1.81

Valuation

Market Cap: $14M
Enterprise Value: $8.5M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-9.8M
Revenue: $2.0M
Net Income: $-9.6M
Cash: $5.2M
Debt: $0

Events

EarningsAug 4

EPS est. -0.47